new warnings about reports of acute pancreatitis with sitagliptin (Januvia, Janumet)<Incretin Enhancers/Mimetics<Treatment<Diabetes<Diabetes and Endocrinology: Pharmacist's Letter

Pharmacist’s Letter addresses the drug therapy issues facing pharmacists. For example:

Does sitagliptin (Januvia) and sitagliptin/metformin (Janumet) increase the risk for pancreatitis?
What is the possible mechanism for acute pancreatitis caused by sitagliptin or Byetta (exenatide)?
Is this higher risk of acute pancreatitis a class effect?
How does diabetes itself effect the risk of pancreatitis?
What should diabetes patients do if they develop unexplained abdominal pain?
Should similar precautions be used for the other gliptin, saxagliptin (Onglyza)?

	Login if you are a current subscriber to Pharmacist's Letter.
	Subscribe now to get instant access and the answers you need.

Additional information is available in our Detail-Document:
	Januvia (Sitagliptin) and Pancreatitis
	FDA is revising the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products. Read more...